CIM
NBIX icon

Contravisory Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Contravisory Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-133
Closed -$15.3K – 418
2024
Q3 		$15.3K Buy
133
+16
+14% +$2.19K ﹤0.01% 302
2024
Q2 		$16.1K Buy
+117
New +$16K ﹤0.01% 293
2020
Q4 		– Sell
-1,273
Closed -$122K – 270
2020
Q3 		$122K Hold
1,273
– – 0.04% 179
2020
Q2 		$151K Buy
+1,273
New +$141K 0.06% 169

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Contravisory Investment Management's NBIX Position: Q4 2024 in Review

Contravisory Investment Management sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 133 shares — an estimated $15.3K sold.

Contravisory Investment Management first reported a position in NBIX in Q2 2020 and held it in 4 quarters. The position peaked at $151K in Q2 2020. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Contravisory Investment Management reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Contravisory Investment Management sold 133 Neurocrine Biosciences shares in Q4 2024, an estimated $15.3K.
  • Contravisory Investment Management first reported a position in Neurocrine Biosciences in Q2 2020 and held it in 4 quarters.
  • Contravisory Investment Management's Neurocrine Biosciences position peaked at $151K in Q2 2020.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Contravisory Investment Management's 13F filing for Q4 2024, filed 14 Jan 2025.